Overview
McDermott Will & Emery advised Osivax, a biopharmaceutical company developing broad-spectrum vaccines against highly mutated infectious viruses, on exclusive license option agreement granting KM Biologics Co, Ltd, a leading vaccine manufacturer in Japan, an exclusive license option to develop, manufacture and commercialize Osivax’s broad-spectrum “universal” influenza vaccine candidates for the Japanese market.
The McDermott team on this deal included Anne-France Moreau (Partner – Paris) and Caroline Noyrez (Associate – Paris).
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
